In a webcast hosted by the Alliance for Health Policy that took place earlier this week, Robert Langreth, senior health reporter for Bloomberg News, Dora Hughes, MD, MPH, senior policy advisor at Sidley Austin, LLP, and Sameer Awsare, MD, associate executive director of the Permanente Medical Group at Kaiser Permanente, came together to discuss the best ways to bring down the steadily increasing drug prices in the United States. The panel was moderated by Mary Ella Payne, RN, MSPH, president of the Alliance for Health Policy.
In a webcast hosted by the Alliance for Health Policy that took place earlier this week, Robert Langreth, senior health reporter for Bloomberg News, Dora Hughes, MD, MPH, senior policy advisor at Sidley Austin, LLP, and Sameer Awsare, MD, associate executive director of the Permanente Medical Group at Kaiser Permanente, came together to discuss the best ways to bring down the steadily increasing drug prices in the United States. The panel was moderated by Mary Ella Payne, RN, MSPH, president of the Alliance for Health Policy.
Langreth opened the discussion by providing background on how drug pricing functions in the United States, and the differences between brand-name drug pricing and generic drug pricing practices. Langreth pointed out that the list price of a drug does not include any rebates negotiated by the pharmacy benefit managers. Historically, however, these list prices have been increasing at alarming rates. He provided an example of reference adalimumab (Humira), which had a list price of $762 in 2009, and with added discounts, the price decreased to around $630. However, as of 2015, the list price rose 127% to $1728, with added discounts only bringing it down to $1331.
The main difference between pricing of brand-name or generic drugs is that, while brand name prices go up, on average, generic prices tend to go down. “[The pricing] of generics is of growing importance because 80% to 90% of prescriptions filled in the United States are generic,” said Langreth.
Building on the discussion, Hughes gave an overview of the “American Patient’s First” plan, jointly announced by President Trump and HHS Secretary Alex Azar in a press conference last month, and credited the FDA and its Commissioner, Scott Gottlieb, MD, “for leading the charge on addressing the high cost of drugs.” Gottlieb, she pointed out, has released a drug competition plan that includes multiple actions the FDA is taking to promote competition within the pharmaceutical industry. Included within this strategy is the forthcoming Biosimilar Innovation Plan, designed to promote the development and efficient review process of biosimilars.
Awsare added his thoughts on the issue of drug pricing, stating that “Drug pricing in our country is broken. The average drug price of a specialty drug now exceeds the median US household income. The system is not working.” Awsare sees the problem being alleviated in 3 ways: increased transparency, competition, and value.
Awsare also went on to discuss the value that biosimilars have in the market, and his experience with physicians using biosimilars at Kaiser Permanente. “When Zarxio came out, we had our physicians look at the data and compare the numbers between the biosimilar and the reference and immediately saw the value. I think we’ve been leading the nation with using biosimilars because we can get our physicians to look at the evidence and move their patients over to the product,” said Awsare.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.